Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- New drug can prevent mild to life-threatening anaphylaxis, shows studyon June 3, 2020 at 8:55 am
For someone with a food or drug allergy, the risk of life-threatening anaphylactic shock lurks around every corner. A new Northwestern Medicine study shows there might be a pill that can be taken ...
- Replimune lead drug shows benefit in non-melanoma skin canceron June 3, 2020 at 4:52 am
(NASDAQ:REPL) announces new data from a Phase 1/2 clinical trial evaluating the combination of lead candidate RP1 and Bristol Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) in patients with so ...
- AGEN, AGE To Battle Coronavirus, BCLI Awaits ALS Trial Data, FDA Delays Decision On NVS' Drugon June 2, 2020 at 11:48 pm
Today's Daily Dose brings you news about Agenus' foray into COVID-19 drug development space; AMERI Holdings' progress in glioblastoma multiforme drug development; BrainStorm Cell's anticipated ...
- Antimalarial drug boosts glioblastoma treatmenton June 2, 2020 at 7:15 am
Scientists find that an already-approved antimalarial drug shows promise in making radiation and chemotherapy treatment of glioblastoma more successful.
- Chemotherapy-induced Nausea and Vomiting Drugs Market 2020: Covid 19 Impact Analysis As Key Facts And Forecast Predictions Provided Till 2025on June 1, 2020 at 10:50 pm
Jun 02, 2020 (The Expresswire) -- "Chemotherapy-induced Nausea and Vomiting Drugs Market" 2020-2025 Report Provides Market Share, CAGR, ...
- Relugolix: Novel Drug for ADT in Advanced Prostate Canceron June 1, 2020 at 12:04 pm
Investigational agent relugolix was non-inferior to leuprolide but also significantly cut the risk of major adverse cardiovascular events.
- Drug could boost survival from lung cancer affecting non-smokerson June 1, 2020 at 10:00 am
The drug Tagrisso could offer hope to patients battling a form of lung cancer that typically hits people with little or no history of smoking, a new trial finds.
- Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)on June 1, 2020 at 2:29 am
Antibody-Drug Conjugates (ADCs) developed as a targeted treatment approach to deliver toxins directly to cancer cells are one of the fastest growing classes of oncology therapeutics, with eight ADCs ...
- Blueprint gets FDA priority review for competitor to newly approved Lilly cancer drugon May 31, 2020 at 8:24 am
Phase I/II data for pralsetinib in non-small cell lung cancer are the subject of a poster presented at the ASCO meeting. An expert noted the similarity between its clinical activity and that of ...
via Bing News